155380-11-3

Usage

Uses

Used in Cosmetic and Personal Care Industry:
Methyl 2-(4-(hydroxymethyl)phenyl)acetate is used as a fragrance ingredient for its ability to impart a sweet, floral aroma to various cosmetic and personal care products, enhancing their sensory appeal.
Used in Perfumery:
In the manufacturing of perfumes, Methyl 2-(4-(hydroxyMethyl)phenyl)acetate is used as a scent component to provide a distinctive, sweet, and floral note, contributing to the overall fragrance profile.
Used in Soap Production:
Methyl 2-(4-(hydroxymethyl)phenyl)acetate is used as a fragrance enhancer in soaps, adding a pleasant, aromatic scent that improves the product's olfactory experience.
Used in Pharmaceutical Industry:
Methyl 2-(4-(hydroxyMethyl)phenyl)acetate is utilized as a flavoring agent in oral medications, improving the taste and palatability of pharmaceutical products.
Used in Food and Beverage Industry:
In the food and beverage sector, Methyl 2-(4-(hydroxyMethyl)phenyl)acetate is used to add fragrance to various products, enhancing their aroma and overall sensory attributes.

Upstream product

• 7398-42-7 methyl 2-(4-(bromomethyl)phenyl)acetate 
• 73401-74-8 4-hydroxymethylphenylacetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 622-47-9 4-tolylacetic acid 
• 74-88-4 methyl iodide 
• 67-56-1 methanol 
• 13737-36-5 4-bromophenylacetic acid 

Downstream Products

• 834914-24-8 {4-[6-(2-dimethylamino-propionyl)-naphthalen-2-yloxymethyl]-phenyl}-acetic acid methyl ester 
• 96524-70-8 methyl 2-(4-formylphenyl)acetate 
• 789457-36-9 [4-(3-amino-propyl)-phenyl]-acetic acid methyl ester 
• 808753-11-9 [4-(3-methanesulfonylamino-propyl)-phenyl]-acetic acid methyl ester 
• 808753-12-0 [4-(3-methanesulfonylamino-propyl)-phenyl]-acetic acid 
• 808753-10-8 [4-(2-cyano-vinyl)-phenyl]-acetic acid methyl ester 
• 155380-03-3 methyl 2-(4-(((tert-butyldimethylsilyl)oxy)methyl)phenyl)acetate 
• 1253955-08-6 methyl 2-(4-(((triisopropylsilyl)oxy)methyl)phenyl)acetate 
• 1456814-33-7 methyl [4-({[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino-[4,3-i]isochromen-10-yl]oxy}methyl)phenyl]acetate 
• 1456814-28-0 N-[3-(dimethylamino)propyl]-1-methyl-4-({[1-methyl-4-({[4-({[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}methyl)phenyl]acetyl}amino)-1H-pyrrol-2-yl]carbonyl}amino)-1H-pyrrole-2-carboxamide 
• 1456814-36-0 [4-({[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}methyl)phenyl]acetic acid 
• 1456814-29-1 N-[3-(dimethylamino)propyl]-1-methyl-4-({[1-methyl-4-({[1-methyl-4-({[4-({[(5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl]oxy}methyl)phenyl]acetyl}amino)-1H-pyrrol-2-yl]carbonyl}amino)-1H-pyrrol-2-yl]carbonyl}amino)-1H-pyrrole-2-carboxamide 
• 1000505-73-6 2-(4-(1,3-Dioxolan-2-yl)phenyl)ethanol 
• 1613414-62-2 methyl 2-(4-(1,3-dioxolan-2-yl)phenyl)acetate 

Relevant academic research and scientific papers

SS-AMINO ACID DERIVATIVE, KINASE INHIBITOR AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME, AND USE OF THE SAME

A compound represented by Formula (I), a pharmaceutically acceptable salt or ester, hydrate, solvate or crystalline form thereof is provided: The compound represented by Formula (I) is a β-amino acid derivative, and in Formula (I): X is a single bond or O; Y is NH or C=O; Z is C=O, C=S, NH, W is C or N; A is a single bond, O, OH, OCH2, a heterocycle or N3; R1 is H or F; R2 is H, F, OH, CF3, CH2OH, CHO or ; R3 is H; n is 0 or 1; and m is 0 or 1.

Nitroxide derivative of ROCK kinase inhibitor

The invention provides a small molecular compound of a NO donor. The small molecular compound is characterized in that the small molecular compound is a compound shown represented by structural formula I shown in the description, or a stereoisomer, a geometrical isomer, a tautomer, a racemate, a deuterated isotope derivative, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof; and in the formula I, ring A is a substituted or unsubstituted heteroaromatic ring, X is selected from (CH2)n, n is selected from 0, 1, 2 and 3, R is a substituent group of terminal -O-NO2, R is selected from hydrogen, a hydroxyl group, halogen, an amino group, a cyano group, a substituted or unsubstituted alkyl group, a substituted or unsubstituted alkoxy group, a substituted or unsubstituted alkenyl group, a substituted or unsubstituted alkynyl group and a substituted or unsubstituted heteroalkyl group, and R and R are respectively and independently selected from hydrogen, a substituted or unsubstituted alkyl group, a substituted or unsubstituted naphthenic base or an amino protecting group, or R and R are connected to form a substituted or unsubstituted cyclic heteroalkyl group. The compound has a high-activity inhibition effect on ROCK kinase.

Asymmetric Synthesis of Netarsudil: A New Therapeutic for Open-Angle Glaucoma

The asymmetric synthesis of a Rho kinase/norepinephrine transport inhibitor, netarsudil, the active component in the recently FDA-approved product Rhopressa, is described herein. This concise six-step synthetic route utilizes the 2,4-dimethylbenzoate ester of a phenylacetic acid as the backbone of the β-amino acid's framework. A chiral enolate of the Evans auxiliary, (R)-4-benzyloxazolidin-2-one, is used to direct the formation of the (S)-stereocenter by incorporating the N -Boc-protected β-amino methyl arm with high diastereoselectivity (96:4 dr) using N -Boc-1-aminomethylbenzotriazole as the electrophile. Uniquely, 2,2,2-trichloro-1,1-dimethylethyl chloroformate is used as a non-racemizing activating agent for the coupling reaction between the chiral (S)- N -Boc-protected 2,4-dimethylbenzoyloxymethyl phenyl propanoic acid and 6-aminoisoquinoline to provide N -Boc-protected netarsudil in good yield and excellent enantiomeric purity (63%, 98% ee). Final acidic deprotection and recrystallization provides netarsudil (>99% ee), an ophthalmic agent used for the treatment of patients with open-angle glaucoma.

IMIDAZOLE-BASED ANTICANCER AGENTS AND DERIVATIVES THEREOF, AND METHODS OF MAKING AND USING SAME

Imidazole-based anticancer agents and derivatives thereof, as well as methods of making and methods of using the same, are described. The imidazole-based anticancer agents are HDAC inhibitor compounds having a 1-(1H-imidazol-2-yl)ethan-1-one or 1-(1H-imidazol-2-yl)ethane-1- thione moiety.

Process for the preparation of kinase inhibitors and intermediates thereof

Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.

PROCESS FOR THE PREPARATION OF KINASE INHIBITORS AND INTERMEDIATES THEREOF

Described are processes for the synthesis of certain compounds, useful for treating diseases, e.g. eye disease, such as glaucoma and ocular hypertension, in a subject.

Identification of Novel Triazole-Based Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors Endowed with Antiproliferative and Antiinflammatory Activity

Nicotinamide phosphoribosyltransferase (NAMPT) is a key enzyme involved in the recycling of nicotinamide to maintain adequate NAD levels inside the cells. It has been postulated to be a pharmacological target, as it is overexpressed in cancer cells as well as in inflammatory diseases. We describe the synthesis and characterization of a novel class of one-digit nanomolar NAMPT inhibitors based on in vitro characterization. The most active compound tested, 30c, displayed activity in xenograft and allograft models, strengthening the potential of NAMPT inhibitors as antitumoral drugs. Furthermore, in the present contribution we describe the ability of 30c to significantly improve the outcome of colitis in mice. Given that this is the first report of an effect of NAMPT inhibitors in colitis, this result paves the way for novel applications for this class of compounds.

2-PHENYL-3H-IMIDAZO[4,5-B]PYRIDINE DERIVATES USEFUL AS INHIBITORS OF MAMMALIAN TYROSINE KINASE ROR1 ACTIVITY

A compound of formula (I′) or (I′′) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

OPTIONALLY FUSED HETEROCYCLYL-SUBSTITUTED DERIVATIVES OF PYRIMIDINE USEFUL FOR THE TREATMENT OF INFLAMMATORY, METABOLIC, ONCOLOGIC AND AUTOIMMUNE DISEASES

Disclosed are compounds active towards nuclear receptors, pharmaceutical compositions containing the compounds and use of the compounds in therapy.

3,3-DIFLUORO-PIPERIDINE DERIVATIVES AS NR2B NMDA RECEPTOR ANTAGONISTS

Disclosed are chemical entities of Formula (I): wherein X, Y, Z, R1, R3, R4 and R5 are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).